Schulich school of Medicine and Dentistry logo Gastroenterology Schulich School of Medicine & Dentistry

Aze Wilson

WilsonApic_2017115x150.jpg

Contact Information

Office: Room A10-221, University Hospital
Tel: 519.685.8500 ext. 33832
Fax: 519.663.3220

Research Interests/Specializations

Biomarkers
Drug metabolism
Inflammatory bowel disease
Pharmacogenomics

Dr. Aze Wilson is a clinical gastroenterologist and an Assistant Professor of Medicine at Western University. She joined the Division of Gastroenterology in 2016 as a Clinician-Researcher with a focus on translational research in inflammatory bowel disease. She also has a cross-appointment with the Division of Clinical Pharmacology and the Department of Physiology & Pharmacology.  Dr. Wilson began her scientific training at Queen's University, where she completed an honours BSc. in Life Sciences.  She completed her medical education at Western University, becoming accredited in both Internal Medicine and Gastroenterology.  She completed the Royal College-certified Clinician-Investigator Program in 2016 in addition to completing her PhD in Physiology and Pharmacology. Her clinical interests include inflammatory bowel disease and other luminal diseases. Her research interests include drug metabolism and drug response in inflammatory bowel disease, with a particular focus on genetic markers of drug response.

Recent Publications

 Wilson A, Wang Q, Ponich T, Gregor JC, Chande N, Yan B, Sey M, Beaton M, Kim RB. Pre-treatment HLADQA1-HLADRB1 testing for the prevention of azathioprine-induced pancreatitis in inflammatory bowel disease: a prospective cohort study.  American Journal of Gastroenterology, 2020 Jul 11, Principal Author [submitted].

Wilson A, Choi B, Sey M, Ponich T, Beaton M, Kim RB.  High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease.  Alimentary Pharmacology & Therapeutics, 2020 Jul 10, Principal Author [submitted].

Imasogie N, Rose RV, Wilson A. High Quantities: Evaluating the Effect of Cannabis Use on Propofol Anesthesia during Endoscopy.  Digestive Diseases & Sciences, 2020 Jul 2, Senior Author [submitted].

Mikail M, Wilson A. Infliximab exposure in large, multifocal, abdominal pyoderma gangrenosum associated with ulcerative colitis: a case report. Sage Open Medical Case Reports, 2020 May 30, Senior Author [submitted]

Wilson A, Beaton MD, Brahmania M. Letter to the editor: non-alcoholic fatty liver disease - one size may not fit all. Hepatology. 2020 May 1, Impact Factor: 14.7, Principal Author [accepted, in press]

Wilson A, Wang Q, Almousa AA, Jansen LE, Choi Y, Schwarz UI, Kim RB. Genetic variation in the Farnesoid X-Receptor Predicts Crohn’s Disease Severity in Female Patients. Scientific Reports, 2020 May 29, Principal Author [accepted, in press]

Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan BG, Gregor JC, Khanna R, Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis, 2020 Jun; 26(6):949-59, Coauthor, DOI: 10.1093/ibd/izz244.

Wilson A, Peel C, Wang Q, Pananos AD, Kim RB. Letter: immunogenicity of infliximab—ready for routine prediction? Authors’ reply. Alimentary Pharmacology & Therapeutics. 2020 Mar 30, 51. (18): p.813-814, Principal Author, DOI: doi.org/10.1111/apt.15684

Wilson A, Peel C, Wang Q, Pananos AD, Kim RB. HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. Aliment Pharmacol Ther, 2020 Feb; 51(3):356-363, Principal Author, DOI: 10.1111/apt.15563.

Wilson A, Almousa A, Teft WA, Kim RB. Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn’s disease. Sci Rep, 2020 Feb 5; 10 (1): 1866, Principal Author, DOI: 10.1038/s41598-020-58644-w.

Wilson A, Urquhart BL, Ponich T, Chande N, Gregor JC, Beaton M, Kim RB. Crohn’s Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression. Mol Pharm, 2019 Sep 3; 16 (9): 4059-4064, Principal Author, DOI: 10.1021/acs.molpharmaceut.9b00459.

Zhu CN, Friedland J, Yan B, Wilson A, Gregor J, Jairath V, Sey M. Presence of Melena in Obscure Gastrointestinal Bleeding Predicts Bleeding in the Proximal Small Intestine. Dig Dis Sci, 2018 May 1; 63 (5): 1280-1285, Coauthor, DOI: 10.1007/s10620-018-5003-x.

Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, Sey M, Beaton M, McIntosh K, Teft WA, Kim RB. Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors’ reply. Aliment Pharmacol Ther. 2018 Apr 1, 47. (7): p.1044-1045, First author, DOI: 10.1111/apt.14562.

Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, Sey M, Beaton M, McIntosh K, Teft WA, Kim RB. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 2018 Mar 1; 47 (5): 615-620, Principal Author, DOI: 10.1111/apt.14483.

Wilson A, Tirona RG, Kim RB. CYP3A4 Activity is Markedly Lower in Patients with Crohn’s Disease. Inflamm Bowel Dis, 2017 Mar 15, Principal Author, DOI: 10.1097/MIB.0000000000001062.

Teft WA, Morse BL, Leake BF, Wilson A, Mansell SE, Hegele RA, Ho RH, Kim RB. Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. Mol Pharm, 2017 Jan 3; 14 (1): 310-318, Co-Author, DOI: 10.1021/acs.molpharmaceut.6b00937.

McLean C, Wilson A, Kim RB. Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant? J Clin Pharmacol, 2016 Jul 1; 56 Suppl 7: S40-58, Coauthor, DOI: 10.1002/jcph.691.

Wilson A, McLean C, Kim RB. Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis. Curr Opin Lipidol, 2016 Apr 1; 27 (2): 148-54, Principal Author, DOI: 10.1097/MOL.0000000000000274.

Wilson A, Teft WA, Morse BL, Choi YH, Woolsey S, DeGorter MK, Hegele RA, Tirona RG, Kim RB. Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. Dig Dis Sci, 2015 Dec 1; 60 (12): 3620-30, Principal Author, DOI: 10.1007/s10620-015-3797-3.

Wilson A, Delport J, Ponich T. Candida glabrata esophagitis: are we seeing the emergence of a new azole-resistant pathogen? International Journal of Microbiology, 2014 Dec; 2014 (2014): Principal Author.

Wilson A, Kim RB. OATP transporters: Potential targets for enhancing organ and tissue specific drug delivery. Journal of Pharmacology and Clinical Toxicology, 2014 Nov; 2 (3): 1037-47, Principal Author

Wilson A, Basharat P, Levstik M, Barra L. Transient elastography for monitoring of liver fibrosis in methotrexate-treated patients with inflammatory disorders: Systematic       Review. Autoimmune Diseases and Clinical Therapeutics, 2014 Oct; 1 (2): 104-110, Co-Principal Author

Wilson A, Patel V, Chande N, Ponich T, Urquhart B, Asher L, Choi Y, Tirona R, Kim RB, Gregor JC. Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther, 2013 Feb 1; 37 (3): 340-5, Principal Author, DOI: 10.1111/apt.12161.

Darling MR, Daley TD, Wilson A, Wysocki GP. Juvenile spongiotic gingivitis. J Periodontol, 2007 Jul 1; 78 (7): 1235-40, Coauthor, DOI: 10.1902/jop.2007.060502.